摘要
目的评价FOLFOX4治疗进展期胃癌的疗效及不良反应。方法总结2002年4月-2006年4月住院进展期胃癌患者126例,随机分为试验组:FOLFOX4组。对照组1:5-FU3000mg/m2静脉滴注120h+TAX(TF组),3周重复。对照组2:5-FU3000mg/m2静脉滴注120h+DDP(FP组),3周重复。按WHO标准评价近期疗效及毒性反应,同时观察中位无进展生存期、中位总生存期。结果FOLFOX4组、TF组、FP组三组总有效率(RR)及临床获益率(RR+SD)分别为:50.0%、48.8%、37.2%及88.1%、87.8%、67.4%,三组中总有效率及临床获益率FOLFOX4、TF组均高于FP组,P<0.05。中位疾病进展时间FOLFOX4组7.27个月、TF组6.16个月、FP组5.70个月,中位总生存期FOLFOX4组10.97个月、TF组9.29个月、FP组9.17个月,统计学分析差异无统计学意义。主要不良反应FOLFOX4方案为外周神经炎、TF方案为血液毒性、FP方案为消化道反应。结论FOLFOX4方案治疗进展期胃癌近期疗效与TF相当,优于FP方案,远期疗效三者差异无统计学意义。
Objective To evaluate the effect ＆ side - effect of FOLFCX4 in treatment of ad- vanced gastric cancer. Methods To summarize the data of 126 cases hospitalized in our hospital between April 2002 to April 2006. The patients were randomly divided into 3 groups. Experimental group ： FOLFOX4 group ：5 - Fu 3000mg/m2 iv. 120h ＋ TAX（ TF group） repeat for 3 weeks. Control group 2 ： 5 - Fu 3000 mg/m2 iv 120h ＋ DDP （ FP group） , repeat for 3 weeks. Evaluate its effect and side - effect, survival time according to WHO criteria. Results The RR and （ RR ＋ SD） of FOLFOX group, TF group and FP group were 50.0% ,48.8% ,37.2% and 88. 1% ,87.8% ,67.4% respectively. The RR and （ RR ＋ SD） of FOLFOX group and TF group are higher than that of FP, P 〈 0.05. The mean disease advance timeFOLFOX4 group 7.27 month,TF group 6. 16 month, FP group 5.70 month. The mean survival time：FOLFOX4 group 10. 97 month,TF group 9.29 month. FP group 9.17 month, theres no statistical difference. Conclusion FOLFOX4 regimen in recent period effect is sire lliar to TF,better than that of FP regimen. There＇ s no obvious difference among the three in aspect of long period effect.
出处
《医药论坛杂志》
2008年第24期9-11,共3页
Journal of Medical Forum
